Posted by M.Popov on 12th Nov 2020
Trial size CTBP2 antibodies available in the Antibody Validation Project
Trial size CTBP2 antibodies available in the Antibody Validation Project
Introduction:
C-terminal binding protein 2 are two distinct proteins produced by the CTBP2 gene. One of them takes part as a corepressor targeting diverse transcription regulators and the other may act as a scaffold for some synapses. Both of them can be found in the cytosol of several tissues including the brain and mutations in this gene can lead to eye disorders and several cancers. CTBP2 is also a prognostic marker in favourable renal cancer and we provide a number of trial sized antibodies, which are suitable for CMKLR1 research purposes, and to help you make the right decision and find the best suited antibody for you, please find the answers to some of the key topics regarding CMKLR1 that we have provided in the links below.
- What is CTBP2?
- Where is CTBP2 found?
- What role does CTBP2 play in disease?
- CTBP2 antibodies in the Antibody Validation project
- Customer reviewed CMKLR1 antibodies
- Other CTBP2 antibodies available in the Antibody Validation Project
- Popular CTBP2 antibodies not currently in the Antibody Validation Project
- How does the Antibody Validation Project work?
What is CTBP2?
This gene produces alternative transcripts encoding two distinct proteins. One protein is a transcriptional repressor, while the other isoform is a major component of specialized synapses known as synaptic ribbons. Both proteins contain a NAD+ binding domain similar to NAD+-dependent 2-hydroxyacid dehydrogenases. The first protein is a corepressor targeting diverse transcription regulators and functions in brown adipose tissue (BAT) differentiation, and the second protein is most likely a scaffold for specialised synapses.
Where is CTBP2 found?
Inside the cell, it is located in the cytosol and has variable levels of nuclear expression in several tissues. Inside the brain, moderate to strong-intensity neuronal somatic immunostaining is noticed.
What role does CTBP2 play in disease?
Mutations in this gene lead to several eye diseases and cancers. Retinitis Pigmentosa is characterised with breaking down and loss of retina cells and loss of peripheral vision and is closely related to this gene. Furthermore, Congenital Stationary Night Blindness is also associated with mutations of CTBP2.
CTBP2 antibodies in the Antibody Validation project
St John's Laboratory offers a variety of trial size primary antibodies which target CTBP2, which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.
Customer reviewed CTBP2 antibodies
| Model | Name | Host | Clonality | Rating | Application Tested |
|---|---|---|---|---|---|
| STJ92514 | Anti-CtBP2 antibody | Rabbit | Polyclonal | 4 | IHC |
Other CTBP2 antibodies available in the Antibody Validation Project
Currently we do not have any CTBP2 antibodies available in the AVP.
Popular CTBP2 antibodies not currently in the Antibody Validation Project
| Model | Name | Host | Clonality | Recommended Applications |
|---|---|---|---|---|
| STJ116173 | Anti-CTBP2 Antibody | Rabbit | Polyclonal | WB |
| STJ119192 | Anti-CTBP2 Antibody | Rabbit | Polyclonal | WB,IF |
How does the Antibody Validation Project work?
In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.
The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.
Find out more here.